Kwality Pharmaceuticals Ltd

Sequentially, the company's consolidated net profit surged 69.87% while net sales jumped 37.05% in Q4 FY25 over Q3 FY25. Profit before tax and exceptional items stood at Rs 19.07 crore in Q4 FY25, up 45.80% year-on-year and up 67.43% QoQ. The company reported one time expense of Rs 7.09 crore in Q4 March 2024. For the full year, adjusted net profit rose 36.99% to Rs 39.85 crore while net sales increased 20.52% to Rs 370.20 crore in the year ended March 2025 over the year ended March 2024. Profit before tax and exceptional items rose 42% year-on-year to Rs 54.14 crore in FY25 over FY24. The company's net cash from operating activities stood at Rs 52.72 crore in FY25, higher than Rs 42.98 crore in FY24. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. Powered by Capital Market - Live

Net profit of Kwality Pharmaceuticals rose 232.34% to Rs 14.49 crore in the quarter ended March 2025 as against Rs 4.36 crore during the previous quarter ended March 2024. Sales rose 25.77% to Rs 115.68 crore in the quarter ended March 2025 as against Rs 91.98 crore during the previous quarter ended March 2024. For the full year,net profit rose 67.44% to Rs 39.85 crore in the year ended March 2025 as against Rs 23.80 crore during the previous year ended March 2024. Sales rose 20.52% to Rs 370.20 crore in the year ended March 2025 as against Rs 307.17 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales115.6891.98 26 370.20307.17 21 OPM %22.3722.43 -21.7221.59 - PBDT24.1618.15 33 72.4357.76 25 PBT19.0713.08 46 54.1438.20 42 NP14.494.36 232 39.8523.80 67 Powered by Capital Market - Live

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

Net profit of Kwality Pharmaceuticals rose 10.92% to Rs 8.53 crore in the quarter ended December 2024 as against Rs 7.69 crore during the previous quarter ended December 2023. Sales rose 8.08% to Rs 84.41 crore in the quarter ended December 2024 as against Rs 78.10 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales84.4178.10 8 OPM %20.7321.36 - PBDT15.9514.57 9 PBT11.399.75 17 NP8.537.69 11 Powered by Capital Market - Live

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live

Kwality Pharmaceuticals (KPL) has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 1U/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD). This milestone marks a significant step forward in our commitment to expanding our biologics portfolio and addressing critical healthcare needs. With this approval, Kwality Pharmaceuticals is on track to complete the pre-clinical studies and is diligently preparing for the commercialization of the product in the next fiscal. Powered by Capital Market - Live

Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD). This milestone marks a significant step forward in our commitment to expanding our biologics portfolio and addressing critical healthcare needs. With this approval, Kwality Pharmaceuticals is on track to complete the preclinical studies and is diligently preparing for the commercialization of the product in the next fiscal. Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers, and sellers of and dealers in all kinds of drug intermediates, chemicals, extracts, alkaloids, and other pharmaceutical goods, toilet requisites, medicines, beverages, and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

The approval was granted through a site transfer process for the company's prominent oncology oral solid dosage (OSD) product. This approval is a significant achievement in expanding the availability of this critical therapeutic, which plays a vital role in the treatment of hormone receptor-positive breast cancer. It reflects its ongoing commitment to providing high-quality, accessible oncology treatments to patients in key markets. The firm said, 'This approval further strengthens our presence in the High Regulated and global oncology market.' Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers and sellers of and dealers in all kind of drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

L-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation process enhances the stability of the molecule and reduces the risk of allergic reactions, thereby improving patient outcomes and treatment efficacy. The company stated, 'This significant milestone underscores our commitment to delivering high-quality therapeutic solutions and marks an important step forward, as it is our first product from the biologics portfolio to be commercialized in both domestic and export markets', the firm stated. In addition, the company is actively engaged in discussions with leading domestic B2B companies to offer its PEGylated-Asparaginase on a CDMO (Contract Development and Manufacturing Organization) basis. These collaborations aim to leverage our manufacturing expertise, ensuring wider availability of this critical therapy. This approach not only strengthens local partnerships but also enhances patient access across various regions. Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers and sellers of and dealers in all kind of drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live